SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing immunotherapies for blood cancers and solid tumors, led by galinpepimut-S (GPS), a WT1-targeted cancer vaccine licensed from Memorial Sloan Kettering, and the CDK9 inhibitor SLS009 (tambiciclib). The stock traded at $19.80 in the current session, up $0.65 or 3.39%, versus the prior close of $19.15. The direction is firmly higher. No fresh press release explains the gain; the move is a rebound from the dilution-driven pullback that followed Tuesday's $150 million underwritten offering announcement, while the market continues to reprice the company around positive Phase 3 REGAL results.
The single most important new item on the tape is the proposed $150 million underwritten public offering launched shortly after Tuesday's close, with J.P. Morgan and TD Cowen as joint book-running managers and a 30-day option for up to $22.5 million in additional shares. The stock fell roughly 10% to 11% in after-hours trading as investors priced in dilution, dropping to the $17.00–$17.26 area.
Wednesday's session tells a different story. Shares opened near $19.50, sold off to $17.22 in the first quarter-hour, then reversed sharply to a session high of $21.16 before settling around $19.80. That round trip is consistent with the offering discount being absorbed rather than treated as a change in the fundamental case. On a roughly $4 billion market capitalization, $150 million of new equity is meaningful but not transformative, and the capital strengthens a balance sheet that already held $134.7 million in cash and equivalents at September 30.
Nothing published today alters the trial readout. SELLAS reported that the 126-patient REGAL study met its primary endpoint, with GPS reducing the risk of death by 41% (hazard ratio 0.59) and median overall survival of 24.0 months versus 14.7 months for best available treatment, at a two-sided p-value of 0.035. Management intends to meet with the FDA on an accelerated filing strategy and is preparing a BLA submission in the first half of 2027.
The debate is about magnitude, not existence. Analysts have flagged that the p-value sits only modestly below the conventional threshold, that no confidence interval accompanied the topline release, and that the control arm allowed observation alone. Those points explain why the stock closed Tuesday at $19.15, far below its $24.89 intraday peak, and why it is still searching for a new equilibrium.
Roughly 57.1 million shares were sold short before the rally, equal to about 28% of the float, with a short ratio near 8.6 days. That positioning makes violent two-way swings the norm: short covering likely contributed to Tuesday's melt-up and to today's rapid recovery off the session low, while profit-taking from newly profitable longs caps upside. Selling pressure also reflects holders who bought Tuesday's spike and are now managing risk around an unresolved offering.
Volume remains elevated. About 4.5 million shares changed hands in the first half hour, well ahead of the roughly 7 million shares the stock typically trades in a full session, though far below Tuesday's 119 million-plus share turnover. The stock sits dramatically above its 50-day moving average near $11.01 and 200-day average near $8.88, with a relative strength index that had already reached 76.6 before today. The $17.22 session low and the $24.89 52-week high frame the near-term range. This is a stock-specific story: the broader market was weak on the day of the trial news, and no sector-wide catalyst accounts for the action.
A score of 0 would mean no meaningful news and a normal move for the stock; 100 would mean transformative news and an extreme, rare price move. SLS earns 20 out of 100.
The verified news is moderate rather than transformative: a $150 million follow-on offering that represents roughly 4% of market value and mainly addresses dilution, layered on a trial result already priced on Tuesday. The price move was unremarkable by this stock's standards. Shares rose 3.39%, about half the 6.7% average absolute daily move over the last 69 completed sessions, and moves of similar or larger size occurred in roughly three dozen of those sessions. Weak news and a routine move combine into a low score.
The immediate catalyst is pricing of the offering, which will set the entry point for new institutional holders and reveal the depth of demand generated by the REGAL result. Beyond that, investors will focus on the FDA meeting and whether an accelerated pathway is confirmed, with a BLA targeted for the first half of 2027. Full REGAL data, including subgroup analyses and adverse-event detail, are expected at a future medical conference and in a peer-reviewed publication. In December, SLS009 data in newly diagnosed AML will be presented at the American Society of Hematology meeting, with preliminary findings from a 40-patient study expected before year-end. Risks include dilution, regulatory interpretation of a narrowly significant endpoint, manufacturing and launch costs, competitive pressure in AML maintenance, and the possibility of sharp reversals given the stock's volatility and elevated short interest.
Tickeron maintains hundreds of AI-driven trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. Bots differ by strategy, holding timeframe, performance metrics and the symbols they trade, so the lineup shifts as conditions change. For readers tracking volatile names like SLS, the page offers a practical, data-driven starting point for evaluating which automated approaches are keeping pace with the tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology